VIVS

VivoSim is a $2.55M-market-cap nano-cap that just reinvented itself. In March 2025 it sold its lead FXR314 IBD drug program for $10M upfront (plus up to $50M in contingent milestones), abandoned clinical development, and rebranded from a clinical-stage biotech into a 3D-human-tissue toxicology *services* company riding the FDA's April 2025 push toward non-animal 'NAM' testing methods. The MD&A's headline metrics — 87.5% liver-tox sensitivity, 100% specificity — are scientifically encouraging, but the P&L shows this is essentially a pre-revenue concept: FY2025 revenue was just $144K (+32% YoY off a trivial base), and the four-year revenue line ($0 → $1.5M → $370K → $109K → $144K) shows no durable commercial traction whatsoever. The only reason net loss narrowed to -$2.49M (from -$14.7M) is the one-time gain on the FXR sale; true operating loss was -$12.6M and operating cash burn was -$9.46M.

The balance sheet looks superficially healthy — $11.3M cash, $10.5M equity, low 0.40x liabilities/equity — but that cash is a melting ice cube. Against a -$9.46M annual burn, the FY2025 cash pile is barely ~14 months of runway, and R&D alone runs $5.0M. With only 2.60M shares outstanding after an ~82% share-count reduction (a reverse split), and a -$342M accumulated deficit, this company has destroyed enormous capital and will almost certainly need to raise again — meaning dilution or another structural action is the base case, not a tail risk.